Top

Allergy, Asthma & Clinical Immunology

Published in:

01-12-2020 | Allergic Rhinitis | Research

Relationship between serum inhibitory activity for IgE and efficacy of Artemisia pollen subcutaneous immunotherapy for allergic rhinitis: a preliminary self-controlled study

Authors: Wenping Wang, Jinshu Yin, Xueyan Wang, Tingting Ma, Tianfei Lan, Qingkun Song, Yifan Guo

Published in: Allergy, Asthma & Clinical Immunology | Issue 1/2020

Abstract

Background

Biomarkers of clinical efficacy for subcutaneous immunotherapy (SCIT) on allergic rhinitis (AR) have not been identified yet. This study aims to assess the clinical relevance of serum inhibitory activity for IgE by the method of enzyme-linked immunosorbent facilitated antigen binding (ELIFAB) during SCIT for Artemisia-sensitized AR patients.

Methods

19 AR patients were studied who had undergone Artemisia-specific SCIT for more than 8 months (19.68 months on average, ranging from 9 to 33 months). Peripheral bloods were collected before and after treatment. The serum inhibitory activity for IgE was tested by ELIFAB and the level of Artemisia-specific IgG4 (Artemisia-sIgG4) was determined by ELISA. Clinical improvement was evaluated based on the symptom scores and rescue medication use (SMS). The 2-tailed Wilcoxon signed-rank test and the Spearman rank test (two-tailed) were used to analyze data by using SPSS 20.0, with P values of less than 0.05 considered as significant.

Results

The SMS decreased significantly after SCIT (before: 12.79 ± 4.250, after: 6.11 ± 3.828, P = 0.000 < 0.01), the treatment was remarkably effective for 6 patients, effective for 10 and ineffective for 3, along with a total effective rate 84.21%. The serum inhibitory activity for IgE increased significantly after SCIT (P < 0.05) and was correlated with the levels of Artemisia-sIgG4 (r = − 0.501, P = 0.002 < 0.01). The levels of Artemisia-sIgG4 elevated dramatically after treatment (P < 0.01) and were related with the duration of treatment (r = 0.558, P = 0.000 < 0.01). But there was no relationship between clinical improvements and the serum inhibitory activity for IgE.

Conclusions

The serum inhibitory activity for IgE increased significantly after SCIT, however, there was no correlation between it and clinical improvements by statistics analysis. So whether the serum inhibitory activity for IgE can act as biomarker of efficacy for SCIT or not needs to be studied further.

Available only for authorised users

Bao Y, Chen J, Cheng L, Guo Y, Hong S, Kong W, et al. Chinese Guideline on allergen immunotherapy for allergic rhinitis. J Thorac Dis. 2017;9:4607–50.PubMedPubMedCentralCrossRef

Wang XD, Zheng M, Lou HF, Wang CS, Zhang Y, Bo MY, et al. An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005 to 2011. Allergy. 2016;71:1170–80.PubMedCrossRef

Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol. 2015;136:556–68.PubMedCrossRef

Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126:466–76.PubMedCrossRef

Dhami S, Nurmatov U, Arasi S, Khan T, Asaria M, Zaman H, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. Allergy. 2017;72:1597–631.PubMedCrossRef

Chen S, Zheng Y, Chen B, Zhong H, Liao F, Wang L, et al. Clinical Response to Subcutaneous Dermatophagoides pteronyssinus Immunotherapy in Children with Allergic Rhinitis and Asthma Is Independent of Sensitization to Blomia tropicalis Allergens. Int Arch Allergy Immunol. 2019;178:201–10.PubMedCrossRef

Boonpiyathad T, Sokolowska M, Morita H, Ruckert B, Kast JI, Wawrzyniak M, et al. Der p 1-specific regulatory T-cell response during house dust mite allergen immunotherapy. Allergy. 2018;74(5):976–85.CrossRef

Scadding GW, Eifan AO, Lao-Araya M, Penagos M, Poon SY, Steveling E, et al. Effect of grass pollen immunotherapy on clinical and local immune response to nasal allergen challenge. Allergy. 2015;70:689–96.PubMedCrossRef

Shamji MH, Wilcock LK, Wachholz PA, Dearman RJ, Kimber I, Wurtzen PA, et al. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods. 2006;317:71–9.PubMedPubMedCentralCrossRef

10.

Feng M, Su Q, Lai X, Xian M, Shi X, Wurtzen PA, et al. Functional and Immunoreactive Levels of IgG4 correlate with clinical responses during the maintenance phase of house dust mite immunotherapy. J Immunol. 2018;200:3897–904.PubMedCrossRef

11.

Shamji MH, Kappen J, Abubakar-Waziri H, Zhang J, Steveling E, Watchman S, et al. Nasal Allergen Neutralising IgG4 Antibodies Block IgE-mediated Responses: novel biomarker of Subcutaneous Grass Pollen Immunotherapy. J Allergy Clin Immunol. 2018;143(3):1067–76.PubMedCrossRef

12.

Shamji MH, Kappen JH, Akdis M, Jensen-Jarolim E, Knol EF, Kleine-Tebbe J, et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper. Allergy. 2017;72:1156–73.PubMedCrossRef

13.

Santos AF, James LK, Bahnson HT, Shamji MH, Couto-Francisco NC, Islam S, et al. IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens. J Allergy Clin Immunol. 2015;135:1249–56.PubMedPubMedCentralCrossRef

14.

Shamji MH, Francis JN, Wurtzen PA, Lund K, Durham SR, Till SJ. Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: inhibition by blocking antibody responses after immunotherapy. J Allergy Clin Immunol. 2013;132:1003–5.PubMedCrossRef

15.

Arzt L, Bokanovic D, Schrautzer C, Laipold K, Mobs C, Pfutzner W, et al. Immunological differences between insect venom-allergic patients with and without immunotherapy and asymptomatically sensitized subjects. Allergy. 2018;73:1223–31.PubMedCrossRef

16.

Mobs C, Muller J, Rudzio A, Pickert J, Blank S, Jakob T, et al. Decline of Ves v 5-specific blocking capacity in wasp venom-allergic patients after stopping allergen immunotherapy. Allergy. 2015;70:715–9.PubMedCrossRef

17.

Lou HF, Ma SY, Zhao Y, Cao FF, He F, Wang XD, et al. Minimum battery of test inhalant allergens needed in screeningsquareallergic rhinitis patients in Beijing. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2018;32:37–42.PubMed

18.

Lombardero M, Garcia-Selles FJ, Polo F, Jimeno L, Chamorro MJ, Garcia-Casado G, et al. Prevalence of sensitization to Artemisia allergens Art v 1, Art v 3 and Art v 60 kDa. Cross-reactivity among Art v 3 and other relevant lipid-transfer protein allergens. Clin Exp Allergy. 2004;34:1415–21.PubMedCrossRef

19.

Diaz-Perales A, Lombardero M, Sanchez-Monge R, Garcia-Selles FJ, Pernas M, Fernandez-Rivas M, et al. Lipid-transfer proteins as potential plant panallergens: cross-reactivity among proteins of Artemisia pollen, Castanea nut and Rosaceae fruits, with different IgE-binding capacities. Clin Exp Allergy. 2000;30:1403–10.PubMedCrossRef

20.

Garcia-Selles FJ, Diaz-Perales A, Sanchez-Monge R, Alcantara M, Lombardero M, Barber D, et al. Patterns of reactivity to lipid transfer proteins of plant foods and Artemisia pollen: an in vivo study. Int Arch Allergy Immunol. 2002;128:115–22.PubMedCrossRef

21.

Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8–160.PubMedCrossRef

22.

Wang XY, Lan TF, Kong R, Chen YL, Wang XY. The sensitization feature of artemisia allergy and the diagnosis value of skin prick test. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2018;32:1860–4.PubMed

23.

Liu Y, Xing Z, Wang J, Geng C. Salivary Immunoglobulin A, E, and G4 Levels Specific to Dermatophagoides pteronyssinus in Allergic Rhinitis Patients Treated With Subcutaneous Immunotherapy. Am J Rhinol Allergy. 2018;32(6):458–64.PubMedCrossRef

24.

Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy. 2007;62:317–24.PubMedCrossRef

25.

Zhao D, Lai X, Tian M, Jiang Y, Zheng Y, Gjesing B, et al. The Functional IgE-Blocking Factor Induced by Allergen-Specific Immunotherapy Correlates with IgG4 antibodies and a decrease of symptoms in house dust mite-allergic children. Int Arch Allergy Immunol. 2016;169:113–20.PubMedCrossRef

26.

Aalberse R. The role of IgG antibodies in allergy and immunotherapy. Allergy. 2011;66(Suppl 95):28–30.PubMedCrossRef

27.

Goldblum RM, Madagoda-Desilva RS, Zhang Y, van Bavel J, Midoro-Horiuti T. Molecular patterns in the isotype-specific antibody responses to the major cedar aeroallergen Jun a 1. Mol Immunol. 2018;101:527–30.PubMedPubMedCentralCrossRef

28.

Flicker S, Steinberger P, Eibensteiner PB, Lebecque S, Kraft D, Valenta R. Molecular characterization of a human immunoglobulin G4 antibody specific for the major birch pollen allergen, Bet v 1. Clin Exp Allergy. 2008;38:365–73.PubMedCrossRef

29.

Sakurai D, Yonekura S, Iinuma T, Sakurai T, Morimoto Y, Mita Y, et al. Sublingual immunotherapy for allergic rhinitis: subjective versus objective tools to evaluate its success. Rhinology. 2016;54:221–30.PubMedCrossRef

30.

Eckl-Dorna J, Villazala-Merino S, Linhart B, Karaulov AV, Zhernov Y, Khaitov M, et al. Allergen-specific antibodies regulate secondary allergen-specific immune responses. Front Immunol. 2019;9:3131.PubMedPubMedCentralCrossRef

31.

Eckl-Dorna J, Villazala-Merino S, Campion NJ, Byazrova M, Filatov A, Kudlay D, et al. Tracing IgE-producing cells in allergic patients. Cells. 2019;8:994.PubMedCentralCrossRef

32.

Vizzardelli C, Gindl M, Roos S, Mobs C, Nagl B, Zimmann F, et al. Blocking antibodies induced by allergen-specific immunotherapy ameliorate allergic airway disease in a human/mouse chimeric model. Allergy. 2018;73:851–61.PubMedCrossRef

33.

Berings M, Gevaert P, De Ruyck N, Derycke L, Holtappels G, Pilette C, et al. FcepsilonRI expression and IgE binding by dendritic cells and basophils in allergic rhinitis and upon allergen immunotherapy. Clin Exp Allergy. 2018;48:970–80.PubMedCrossRef

34.

Gonzalez-de-Olano D, Alvarez-Twose I. Mast cells as key players in allergy and inflammation. J Investig Allergol Clin Immunol. 2018;28:365–78.PubMedCrossRef

35.

Reginald K, Eckl-Dorna J, Zafred D, Focke-Tejkl M, Lupinek C, Niederberger V, et al. Different modes of IgE binding to CD23 revealed with major birch allergen, Bet v 1-specific monoclonal IgE. Immunol Cell Biol. 2013;91:167–72.PubMedCrossRef

36.

Tang R, Sun JL, Yin J, Li Z. Artemisia allergy research in China. Biomed Res Int. 2015;2015:179426.PubMedPubMedCentral

37.

Wang XY, Ma TT, Wang XY, Zhuang Y, Wang XD, Ning HY, et al. Prevalence of pollen-induced allergic rhinitis with high pollen exposure in grasslands of northern China. Allergy. 2018;73:1232–43.PubMedCrossRef

38.

Asero R, Wopfner N, Gruber P, Gadermaier G, Ferreira F. Artemisia and Ambrosia hypersensitivity: co-sensitization or co-recognition? Clin Exp Allergy. 2006;36:658–65.PubMedCrossRef

39.

Wopfner N, Gadermaier G, Egger M, Asero R, Ebner C, Jahn-Schmid B, et al. The spectrum of allergens in ragweed and mugwort pollen. Int Arch Allergy Immunol. 2005;138:337–46.PubMedCrossRef

40.

Gadermaier G, Wopfner N, Wallner M, Egger M, Didierlaurent A, Regl G, et al. Array-based profiling of ragweed and mugwort pollen allergens. Allergy. 2008;63:1543–9.PubMedCrossRef

41.

Leonard R, Wopfner N, Pabst M, Stadlmann J, Petersen BO, Duus JO, et al. A new allergen from ragweed (Ambrosia artemisiifolia) with homology to art v 1 from mugwort. J Biol Chem. 2010;285:27192–200.PubMedPubMedCentralCrossRef

42.

Pablos I, Eichhorn S, Machado Y, Briza P, Neunkirchner A, Jahn-Schmid B, et al. Distinct epitope structures of defensin-like proteins linked to proline-rich regions give rise to differences in their allergenic activity. Allergy. 2018;73:431–41.PubMedCrossRef

43.

Pablos I, Egger M, Vejvar E, Reichl V, Briza P, Zennaro D, et al. Similar allergenicity to different artemisia species is a consequence of highly cross-reactive art v 1-Like molecules. Medicina (Kaunas). 2019;55:504.PubMedCentralCrossRef

44.

Antico A. Long-term adherence to sublingual therapy: literature review and suggestions for management strategies based on patients’ needs and preferences. Clin Exp Allergy. 2014;44:1314–26.PubMedCrossRef

Title: Relationship between serum inhibitory activity for IgE and efficacy of Artemisia pollen subcutaneous immunotherapy for allergic rhinitis: a preliminary self-controlled study
Authors: Wenping Wang
Jinshu Yin
Xueyan Wang
Tingting Ma
Tianfei Lan
Qingkun Song
Yifan Guo
Publication date: 01-12-2020
Publisher: BioMed Central
Keyword: Allergic Rhinitis
Published in: Allergy, Asthma & Clinical Immunology / Issue 1/2020
Electronic ISSN: 1710-1492
DOI: https://doi.org/10.1186/s13223-020-0416-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Relationship between serum inhibitory activity for IgE and efficacy of Artemisia pollen subcutaneous immunotherapy for allergic rhinitis: a preliminary self-controlled study

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Epinephrine auto-injector needle length

Analysis of maternal and perinatal determinants of allergic sensitization in childhood

A contemporary look at allergic conjunctivitis

The clinical, immunological and genetic features of 12 Chinese patients with STAT3 mutations

Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial

Epidermal growth factor upregulates expression of MUC5AC via TMEM16A, in chronic rhinosinusitis with nasal polyps